Distracting Program. In the event that RBNC or its Affiliate or its Sublicensee gains rights to a Distracting Program, then RBNC shall provide prompt written notice (in all events within [***] days of gaining such rights) to AMGEN and include in such notice whether RBNC elects to treat all Distracting Product(s) that are the subject of such Distracting Program as “Product(s)” under this Agreement.
Appears in 4 contracts
Samples: Exclusive License Agreement for Ck1d (Neumora Therapeutics, Inc.), Exclusive License Agreement for Gcase (Neumora Therapeutics, Inc.), Exclusive License Agreement for Gcase (Neumora Therapeutics, Inc.)
